LSV Asset Management
ENTA icon

LSV Asset Management’s Enanta Pharmaceuticals ENTA Stock Holding History

LSV Asset Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-72,200
Closed -$2.38M – 1031
2015
Q4 		$2.38M Sell
72,200
-180,777
-71% -$5.89M 0.01% 622
2015
Q3 		$9.14M Buy
252,977
+161,677
+177% +$6.94M 0.02% 400
2015
Q2 		$4.11M Buy
+91,300
New +$3.55M 0.01% 519

Other funds holding ENTA

ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

LSV Asset Management's ENTA Position: Q1 2016 in Review

LSV Asset Management sold out of Enanta Pharmaceuticals (ENTA) in Q1 2016, closing a stake of 72,200 shares — an estimated $2.38M sold.

LSV Asset Management first reported a position in ENTA in Q2 2015 and held it in 3 quarters. The position peaked at $9.14M in Q3 2015. 153 funds tracked by Wall St. Rank hold ENTA as of Q1 2016.

  • LSV Asset Management reported no remaining Enanta Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • LSV Asset Management sold 72,200 Enanta Pharmaceuticals shares in Q1 2016, an estimated $2.38M.
  • LSV Asset Management first reported a position in Enanta Pharmaceuticals in Q2 2015 and held it in 3 quarters.
  • LSV Asset Management's Enanta Pharmaceuticals position peaked at $9.14M in Q3 2015.
  • 153 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2016.

Based on LSV Asset Management's 13F filing for Q1 2016, filed 10 May 2016.